The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...

Abstract and Introduction Objective: To assess the bioequivalence of beclomethasone dipropionate (BDP) delivered from a press-and-breathe (PB) inhaler and a breath-actuated inhaler (Autohaler TM ...

Participants were randomly assigned to receive beclomethasone dipropionate: 400 µg once daily between 08:00 and 09:00 (OD AM); 400 µg once daily between 15:00 and 16:00 (OD PM); and 200 µg ...

The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3. ...

In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder inhalers (DPIs) for respiratory conditions that are more eco-friendly than ...

A statistically significant improvement (8.1% increase; P <.001) was observed in mean forced expiratory volume in 1 second between visits 1 (55.4%) and 3 (63.5%). Mean forced vital capacity also ...

SAN DIEGO — An inhaler with beclomethasone dipropionate, formoterol fumarate and glycopyrronium lowered lung hyperinflation in patients with COPD, according to research presented at the American ...

The dry powder inhaler market size has grown strongly in recent years, growing from $20.18 billion in 2023 to $21.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth ...

Three years later, an equivalent patent was issued as US 3,312,590. Beclomethasone dipropionate was first approved by the US Food and Drug Administration in 1976 as a nasal spray for treating asthma.